ArticleThe journal of headache and pain2026
Trends in migraine-specific medication consumption: a multinational analysis of 73 countries based on IQVIA-MIDAS database, 2015 to 2024.
Article in The journal of headache and pain, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMigraine is a highly prevalent neurological disorder and one of the leading causes of disability worldwide. Despite this immense public health impact, real-world utilization of migraine-specific pharmacotherapies across different income levels remains poorly characterized. This study examines longitudinal consumption trends of migraine-specific medications (MSMs) across 73 countries.
methodsUsing the IQVIA-MIDAS database, region/country-level quarterly sales volumes of specific MSMs and propranolol from 2015 to 2024 were extracted and normalized to standard units per 1000 population. Descriptive statistics were summarized using the median, interquartile range (IQR), population-weighted mean and standard error (SE). For stratified analysis, the 73 countries were classified into high-, upper-middle-, and lower-middle-income countries (HICs, UMICs, LMICs). Temporal trends were evaluated using joinpoint regression to calculate the annual percent change (APC). Multiple intervention interrupted time series (ITS) models assessed the sequential impacts of CGRP introduction (May 2018) and the COVID-19 pandemic (January 2020).
resultsBetween 2015 and 2024, median consumption of all MSMs nearly doubled from 101.77 to 194.39, with population-weighted averages rising from 149.23 to 201.05. The MSM consumption was overwhelmingly concentrated in HICs (337.11 to 378.13), while consumption in UMICs (9.40 to 15.10) and LMICs (18.77 to 28.01) remained persistently low. Acute MSMs, mainly triptans, drove most consumption and showed accelerating growth. Preventive MSM consumption initially declined before rebounding, largely from rapid uptake of CGRP inhibitors in HICs. Propranolol remained the most consistently consumed preventive agent across all income groups. The COVID-19 pandemic coincided with a temporary drop in MSM consumption followed by accelerated long-term growth in several groups.
conclusionsMSM consumption remains markedly unequal and heavily concentrated in HICs. The advanced CGRP inhibitors represent an important therapeutic advance, while underlying gaps in migraine-specific preventive pharmacotherapy largely unresolved. Addressing these global disparities requires healthcare prioritization aligned with the actual disability weight of migraine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.